Laura Figulla

Mbiomics GmbH is a German company that specializes in microbiome analysis. The company is based in Munich, Germany. The company's patented precision technology allows for fast, quantitative, and accurate analysis of the microbiome, which creates a basis for various future clinical applications and accelerates microbiome-based therapeutics development. Mbiomics offers high-resolution measurements of the composition of the microbiome, combining DNA and RNA analysis with a highly standardized workflow and unique single/molecule detection to tackle the three key challenges in microbiome profiling. The company was founded in 2020 by Laura Figulla, Johannes B. Woehrstein, Heinrich Grabmayr, and Laura Figulla has been the CEO since 2020.

coramaze technologies GmbH operates as a medical device company which develops valve repair system. It offers mitramaze a novel concept for transcatheter mitral valve repair intended for treatment of inoperable patients suffering from severe functional mitral regurgitation. The company was founded by Laura Figulla and Till Neumann in 2013 and is headquartered in Munich, Germany.

coramaze technologies GmbH operates as a medical device company which develops valve repair system. It offers mitramaze a novel concept for transcatheter mitral valve repair intended for treatment of inoperable patients suffering from severe functional mitral regurgitation. The company was founded by Laura Figulla and Till Neumann in 2013 and is headquartered in Munich, Germany.

Mbiomics GmbH is a German company that specializes in microbiome analysis. The company is based in Munich, Germany. The company's patented precision technology allows for fast, quantitative, and accurate analysis of the microbiome, which creates a basis for various future clinical applications and accelerates microbiome-based therapeutics development. Mbiomics offers high-resolution measurements of the composition of the microbiome, combining DNA and RNA analysis with a highly standardized workflow and unique single/molecule detection to tackle the three key challenges in microbiome profiling. The company was founded in 2020 by Laura Figulla, Johannes B. Woehrstein, Heinrich Grabmayr, and Laura Figulla has been the CEO since 2020.

coramaze technologies GmbH operates as a medical device company which develops valve repair system. It offers mitramaze a novel concept for transcatheter mitral valve repair intended for treatment of inoperable patients suffering from severe functional mitral regurgitation. The company was founded by Laura Figulla and Till Neumann in 2013 and is headquartered in Munich, Germany.